13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001952142
Total reported value
$580.5M
$580.5M
80 檔
29.6%
In Q3 2025, Stempoint Capital LP's U.S. equity holdings reached a combined market value of $580.5M, distributed across 80 disclosed stock positions.
In Q3 2025, Stempoint Capital LP displayed an active expansion posture, initiating 46 new positions and adding to 17 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 12.72% | +0.08% | +176.72% | |
| 2 | QURE | uniQure N.V. | Stock-Other | 6.11% | +0.46% | -8.81% | |
| 3 | SRRK | Scholar Rock Holding CORP | Stock-Other | 5.42% | -7.59% | +40.99% | |
| 4 | IMVT | Immunovant Inc | Stock-Other | 5.14% | -1.76% | +31.32% | |
| 5 | DNLI | Denali Therapeutics Inc | Stock-Other | 5.05% | -1.57% | EXIT | |
| 6 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.22% | -5.45% | EXIT | |
| 7 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.37% | — | -34.59% | |
| 8 | BHVN | Biohaven Ltd. | Stock-Other | 3.30% | +0.24% | +756.81% | |
| 9 | WVE | Wave Life Sciences Ltd. | Stock-Other | 3.09% | — | +134.37% | |
| 10 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.92% | — | -42.90% | |
| 11 | ABVX | Abivax Sa-adr | Stock-Other | 2.83% | -0.18% | +89.49% | |
| 12 | IDYA | Ideaya Biosciences Inc | Stock-Other | 2.03% | — | +124.15% | |
| 13 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.85% | — | -48.26% | |
| 14 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.84% | — | — | |
| 15 | SRZN | Surrozen Inc | Stock-Other | 1.84% | -0.21% | +3.92% | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.73% | -0.16% | — | |
| 17 | RZLT | Rezolute Inc | Stock-Other | 1.73% | — | +42.34% | |
| 18 | GHRS | GH Research PLC | Stock-Other | 1.56% | — | +440.81% | |
| 19 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.56% | -1.42% | +100.27% | |
| 20 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 1.55% | -0.01% | +3.13% | |
| 21 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.55% | -0.78% | — | |
| 22 | ALKS | Alkermes plc | Stock-Healthcare | 1.45% | +1.70% | -31.18% | |
| 23 | CELC | Celcuity Inc | Stock-Other | 1.35% | +0.46% | — | |
| 24 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.33% | — | +133.27% | |
| 25 | INSM | Insmed Inc | Stock-Healthcare | 1.25% | — | -29.49% | |
| 26 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.20% | -1.76% | EXIT | |
| 27 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.20% | +0.03% | -74.97% | |
| 28 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.16% | — | +17.24% | |
| 29 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.03% | — | — | |
| 30 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.00% | — | — | |
| 31 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.86% | -0.66% | -1.36% | |
| 32 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.84% | — | — | |
| 33 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.75% | — | -84.43% | |
| 34 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.75% | -0.59% | — | |
| 35 | INCY | Incyte CORP | Stock-Healthcare | 0.74% | — | — | |
| 36 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.73% | -1.50% | — | |
| 37 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.64% | — | — | |
| 38 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.64% | -1.12% | +185.95% | |
| 39 | NKTR | Nektar Therapeutics | Stock-Other | 0.61% | — | — | |
| 40 | ASND | Ascendis Pharma A/S | Stock-Other | 0.60% | — | — | |
| 41 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.59% | — | +372.50% | |
| 42 | HROW | Harrow Inc | Stock-Other | 0.56% | — | — | |
| 43 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.55% | — | -30.26% | |
| 44 | EQ | Equillium Inc | Stock-Other | 0.55% | +1.11% | NEW | |
| 45 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.53% | — | — | |
| 46 | CGON | Cg Oncology Inc | Stock-Other | 0.51% | -0.71% | — | |
| 47 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 0.46% | -0.01% | EXIT | |
| 48 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.43% | — | — | |
| 49 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.41% | +5.82% | +17.52% | |
| 50 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.40% | — | -17.09% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | +4.4% | +176.72% | Add |
| 2 | QURE | uniQure N.V. | +3.6% | -8.81% | Trim |
| 3 | WVE | Wave Life Sciences Ltd. | +2.9% | +134.37% | Add |
| 4 | DNLI | Denali Therapeutics Inc | +2.2% | +145.04% | Add |
| 5 | IDYA | Ideaya Biosciences Inc | +1.7% | +124.15% | Add |
| 6 | BHVN | Biohaven Ltd. | +1.4% | +756.81% | Add |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | +1.3% | -48.26% | Add |
| 8 | MLYS | Mineralys Therapeutics Inc | +1.2% | -74.97% | Add |
| 9 | SRZN | Surrozen Inc | +0.9% | +3.92% | Add |
| 10 | DYN | Dyne Therapeutics Inc | +0.9% | — | Add |
| 11 | 260 | Centessa Pharmaceuticals-adr | +0.7% | -34.59% | Add |
| 12 | OCUL | Ocular Therapeutix Inc | +0.6% | — | Add |
| 13 | IMVT | Immunovant Inc | +0.5% | +31.32% | Add |
| 14 | NAMS | NewAmsterdam Pharma Company N.V. | +0.2% | -1.36% | Add |
| 15 | MBX | Mbx Biosciences Inc | 0% | -46.82% | Trim |
| 16 | VTGN | Vistagen Therapeutics Inc | -0.1% | +3.13% | Add |
| 17 | PTGX | Protagonist Therapeutics Inc | -0.1% | +185.95% | Trim |
| 18 | ASND | Ascendis Pharma A/S | -0.1% | — | Add |
| 19 | ✓ | -0.2% | — | Unchanged | |
| 20 | ABUS | Arbutus Biopharma CORP | -0.3% | — | Trim |
| 21 | SRRK | Scholar Rock Holding CORP | -0.4% | +40.99% | Add |
| 22 | ALKS | Alkermes plc | -0.6% | -31.18% | Add |
| 23 | ARQT | Arcutis Biotherapeutics Inc | -0.7% | +100.27% | Trim |
| 24 | AKRO | Akero Therapeutics Inc | -0.9% | +17.24% | Trim |
| 25 | INSM | Insmed Inc | -0.9% | -29.49% | Trim |
| 26 | BBIO | Bridgebio Pharma Inc | -1% | +133.27% | Trim |
| 27 | 4XC1 | Kalvista Pharmaceuticals Inc | -1.3% | -85.32% | Trim |
| 28 | TARA | Protara Therapeutic Inc | -1.3% | -68.20% | Trim |
| 29 | XENE | Xenon Pharmaceuticals Inc | -1.4% | — | Trim |
| 30 | CGON | Cg Oncology Inc | -1.8% | — | Trim |
| 31 | RVMD | Revolution Medicines Inc | -1.9% | — | Trim |
| 32 | SNDX | Syndax Pharmaceuticals Inc | -2% | -38.20% | Trim |
| 33 | MDGL | Madrigal Pharmaceuticals Inc | -3.6% | -84.43% | Trim |
| 34 | ACLXGBX | Arcellx Inc | -5.5% | -94.35% | Trim |
| 35 | ✓ | Merus N V | — | EXIT | Sold out |
| 36 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 37 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 38 | NUVL | Nuvalent Inc-a | — | EXIT | Sold out |
| 39 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
| 40 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 41 | RZLT | Rezolute Inc | — | NEW | New buy |
| 42 | GHRS | GH Research PLC | — | NEW | New buy |
| 43 | SWTXUSD | Springworks Therapeutics Inc | — | EXIT | Sold out |
| 44 | CELC | Celcuity Inc | — | NEW | New buy |
| 45 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 46 | 2655787D | Blueprint Medicines CORP | — | EXIT | Sold out |
| 47 | JAZZ | Jazz Pharmaceuticals plc | — | NEW | New buy |
| 48 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 49 | EWTX | Edgewise Therapeutics Inc | — | EXIT | Sold out |
| 50 | AMLX | Amylyx Pharmaceuticals Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Stempoint Capital LP reported a total U.S. public equity portfolio value of $580.5M across 80 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, QURE, SRRK) accounted for 29.6% of total reported equity market value during Q3 2025.
Top New Position Initiated
CDTX
市值: $14.6M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $14.6M
During Q3 2025, Stempoint Capital LP's top holdings by market value included ROIV (12.7%)、QURE (6.1%)、SRRK (5.4%). The largest single position, ROIV, represented 12.7% of total portfolio value.
In Q3 2025, Stempoint Capital LP made 102 total portfolio adjustments, initiating 46 new buys, adding to 17 positions, trimming 16 holdings, and fully liquidating 23 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.